Difference between revisions of "Histrelin (Vantas)"
Jump to navigation
Jump to search
m |
m |
||
| Line 24: | Line 24: | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
[[Category:Endocrine therapy]] | [[Category:Endocrine therapy]] | ||
| − | [[Category:GnRH | + | [[Category:GnRH agonists]] |
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:FDA approved in 2004]] | [[Category:FDA approved in 2004]] | ||
Revision as of 02:34, 10 October 2018
General information
Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.[1][2][3]
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication
- 10/12/2004: Initial FDA approval "in the palliative treatment of advanced prostate cancer."
Patient drug information
Also known as
- Brand name: Vantas